FasT CAR is proprietary and patented technology. FasT CAR production takes overnight for cell culturing, in contrast to conventional CAR approch where cell culturing usually takes 2-3weeks.
Patients will not have to wait long to receive drug administration.
GC007F, one of the lead program, is redirected to target CD19 for relapsed / refractory B cell acute lymphoblastic leukemia (B-ALL). This product has multiple advantages, including younger phenotype, higher proliferation capabilities, and less exhaustion, and more potent eliminating leukemia malignancies, and capable of infiltrate into bone marrow and spleen.
* Cell production can be completed within 24 hrs since receipt of cells; while lot releasing test remains the same pre current regulation